On March 29, 2021 Redx Pharma (AIM:REDX), the drug discovery and development Company focused on oncology and fibrosis, reported that it will present a poster entitled ‘Mechanism of action of RXC004, a Wnt pathway inhibitor, in genetically-defined models of cancer’ at the American Association for Cancer Research (AACR) (Free AACR Whitepaper) Annual Meeting, being held virtually on 10 April 2021 (Press release, Redx Pharma, MAR 29, 2021, View Source [SID1234577251]).
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
The poster relates to the Company’s lead oncology candidate, RXC004, a selective, orally bioavailable porcupine inhibitor targeting the Wnt signalling pathway. The poster will present preclinical data on the potential for the direct tumour-targeting effects of RXC004 in genetically defined models of cancer.
Poster presentation:
Title: Mechanism of action of RXC004, a Wnt pathway inhibitor, in genetically-defined models of cancer
Abstract: #998
Session name and category: Session PO.ET02.02-Cellular Responses to Anticancer Drugs
About RXC004
RXC004 is a potent, selective, oral small molecule inhibitor of the enzyme, Porcupine, a key activator of Wnt ligands in the Wnt signalling pathway. Aberrant Wnt signalling contributes directly to tumour growth and plays an important role in immune resistance to treatment with immuno-oncology agents such as anti-PD-1 checkpoint inhibitors.
By selecting patients with tumours that have high Wnt ligand dependency, such as tumours with mutations in the RNF43 gene and fusions in the RSPO gene family, RXC004 has an opportunity to directly target tumour in addition to having an immune-enhancing effect.
RXC004 is currently in a phase 1 study, with top line data expected in H1 2021. Clinical proof-ofconcept studies in genetically-selected patients with metastatic colorectal cancer (monotherapy and immuno-oncology combination), genetically selected pancreatic cancer and all comers biliary cancer are expected to initiate following completion of phase 1.